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ABSTRACT
A medical and scientiﬁc multidisciplinary consensus
meeting was held from 29 to 30 November 2013 on
Anti-Doping in Sport at the Home of FIFA in Zurich,
Switzerland, to create a roadmap for the implementation
of the 2015 World Anti-Doping Code. The consensus
statement and accompanying papers set out the
priorities for the antidoping community in research,
science and medicine. The participants achieved
consensus on a strategy for the implementation of the
2015 World Anti-Doping Code. Key components of this
strategy include: (1) sport-speciﬁc risk assessment,
(2) prevalence measurement, (3) sport-speciﬁc test
distribution plans, (4) storage and reanalysis,
(5) analytical challenges, (6) forensic intelligence,
(7) psychological approach to optimise the most
deterrent effect, (8) the Athlete Biological Passport (ABP)
and confounding factors, (9) data management system
(Anti-Doping Administration & Management System
(ADAMS), (10) education, (11) research needs and
necessary advances, (12) inadvertent doping and
(13) management and ethics: biological data. True
implementation of the 2015 World Anti-Doping Code
will depend largely on the ability to align thinking
around these core concepts and strategies. FIFA, jointly
with all other engaged International Federations of
sports (Ifs), the International Olympic Committee (IOC)
and World Anti-Doping Agency (WADA), are ideally
placed to lead transformational change with the
unwavering support of the wider antidoping community.
The outcome of the consensus meeting was the creation
of the ad hoc Working Group charged with the
responsibility of moving this agenda forward.
INTRODUCTION
A medical and scientiﬁc multidisciplinary consensus
meeting was held from 29 to 30 November 2013
on Anti-Doping in Sport at the Home of FIFA in
Zurich, Switzerland, to create a roadmap for the
implementation of the 2015 World Anti-Doping
Code. The papers delivered at the consensus
meeting are published in this themed edition of the
BJSM along with the consensus statement. The con-
sensus statement and accompanying papers set out
the priorities for the antidoping community in
research, science and medicine. This consensus is
timed to coincide with the publication of the 2015
World Anti-Doping Code and brings together the
latest scientiﬁc and medical evidence and reafﬁrms
the commitment of science and medicine in the
ﬁght against doping in sport.
The ﬁght against doping in sport was formally
started by the International Olympic Committee
(IOC) in the 1960s, culminating in the creation of
World Anti-Doping Agency (WADA) in 1999. The
antidoping movement is now poised to take a
major step forward in the ﬁght against doping in
sport by implementing the new 2015 World
Anti-Doping Code and drawing on the major
advances in science and medicine, much of which
are underpinned by research funded by WADA and
the International Federations of sports (IFs). As
such, evidence-based, targeted, sport-speciﬁc and
situation-speciﬁc strategies along with more effect-
ive analysis and improved efﬁciency and intelli-
gence are approaches envisaged to lead to better
deterrence of doping in sport. These strategies,
combined with education and the commitment of
all antidoping organisations (ADOs) to implement
evidence-based programmes, should help protect
the integrity of sport and all those athletes who do
not dope.
Sport-speciﬁc risk assessment
The overall strategy in the ﬁght against doping
must be based on good scientiﬁc evidence, statis-
tical analysis reﬂecting the prevalence of doping
cases and the monitoring of illicit substances. This
assessment must be sport speciﬁc as the risk and
temptation to dope and the doping strategy will
depend largely on the type of sport.1 For example,
within individual sports, endurance athletes in
track and ﬁeld, cycling or cross-country skiing
would choose different substances and methods to
illicitly improve their performance, in contrast to
athletes who depend primarily on strength and
power, such as weight-lifters, wrestlers or athletes
in certain track and ﬁeld disciplines. The situation
in team sports is likely to be different as results
depend primarily on the collective team perform-
ance, albeit that individual athletes could still be
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tempted to dope to improve performance prospects for team
selection.2
The risk assessment must also take into account the timing
during the season when peak performance is desirable and
expected. The longer the preparation period for a particular
event—the so-called ‘out of competition’ period —that may
precede cycling tours or marathon running, the greater the like-
lihood of eluding doping controls and the temptation to illicitly
augment performance during this training period. It is prudent,
therefore, that the IFs along with the organisations of athletes
consider sport-speciﬁc risk assessments. Such assessments should
be reappraised regularly reﬂecting scientiﬁc evidence and infor-
mation derived from forensic intelligence. The IFs, national
antidoping organisations (NADOs), doctors, scientists and para-
medic personnel, together with representatives from WADA and
the WADA-accredited laboratories, must design and formulate
the risk assessment by sharing information with the IFs, the
IOC and other major event organisations. The role of WADA in
this respect is to coordinate information exchange and alert the
IFs and all involved stakeholders of new information on possible
doping substances, methods or approaches that could potentially
help uncover doping.
Prevalence measurement
A recommended approach for deﬁning the scope of the antidop-
ing activity is to measure the prevalence of doping. The use of
appropriate epidemiological tools and the careful interpretation
of survey results with an understanding of the population exam-
ined will allow the extent of the doping problem to be
assessed.3 This can be achieved by conducting questionnaire
surveys as is commonly used in social sciences. Epidemiological
studies can be further enhanced by measuring putative biomar-
kers of doping in doping-control samples. It is essential to carry
out doping prevalence studies in a population of competitors,
and to appropriately interpret the data before deﬁning and
implementing a programme of longitudinal follow-up. This is
particularly important because of the speciﬁcity of different
sports, which can be inﬂuenced differently by doping depending
on the physical and physiological characteristics required for
performance enhancement.
In public health, pandemics are not distributed evenly around
the globe, and environmental, social and economic factors play
an important role in their distribution. The same is true in sport
where doping prevalence may vary as a function of the sport
and the country in which it is practiced. Research recently con-
ducted in track and ﬁeld demonstrated that the prevalence of
abnormal blood proﬁles can vary from 3% to 48% depending
on the country of origin of the athletes.3 4 Certain sports fed-
erations, sports disciplines and even countries may fear total
transparency in examining their ‘doping cultures’ as acknowl-
edgement may hurt their public image. However, a transparent
approach is necessary if the biological monitoring of athletes is
to become an effective tool in the ﬁght against doping.
Sport-speciﬁc test distribution plans
The 2015 World Anti-Doping Code makes speciﬁc reference to
the development of test distribution plans and the necessity for
thoughtful and strategic approaches to testing.5 Such approaches
will ensure that the effective, intelligent and most efﬁcient
testing strategies are adopted. Fundamental to these considera-
tions are the identiﬁcation of areas of sport that might be
deemed to be high risk for doping practices. International
Federations and NADOs will have particular responsibilities in
this respect.
Several elements should feature prominently in the develop-
ment and preparation of a sport-speciﬁc testing programme.
These include consideration of the unique subcultures of sport
and the degree to which doping may have been ‘normalised’
within such subcultures, the history of doping practices within a
sport, the speciﬁc physiological demands of particular events,
emerging training practices, the competitive schedule, recovery
from injury, an awareness of dramatic changes in performance,
an understanding of the supplement marketplace and a familiar-
ity with what is happening ‘on the street’ as well as ‘in the
stadium’.
Continual, ongoing conversation with athletes, coaches and
others in the sport community can provide an enriched under-
standing of the likelihood of doping behaviour and emerging
problematic practices. Successful antidoping programmes of the
future will embody high-quality, intelligent testing practices
rather than high-quantity test volumes.
The implementation of the new World Anti-Doping Code
with the emphasis on more intelligent testing affords a great
opportunity for enhanced, more effective and more efﬁcient
approaches to doping control. The Athlete Biological Passport
(ABP) represents a further opportunity to ensure strategic and
more focused testing. Implicit in the new approaches to doping
control is the necessity for strategic relationships between and
among ADOs at every level. Agreements between IFs, NADOs
and major event organisers addressing shared approaches to
results management and testing strategies—particularly as they
apply to competitors who are part of ABP programmes—will
beneﬁt the antidoping movement.
The perspectives, experiences and strategies of IFs and
NADOs can be integrated so as to permit more timely and cost-
efﬁcient testing, the sharing of intelligence regarding doping
practices and doping practitioners and heightened vigilance of
customs and other civil authorities with regard to the import-
ation and distribution of prohibited substances particularly at
the time of major sporting events. These approaches will beneﬁt
from the developing international ‘community of practice’
represented by leading IFs and NADOs; the development of
that community will itself be stimulated by the growth of stra-
tegic partnerships and cooperative antidoping activities.
Storage and reanalysis
New peptides or designer drugs may be used by athletes who
feel that there are currently no reliable analytical tests available.
However, the 2015 World Anti-Doping Code allows for the
storage of samples for up to 10 years, which markedly trans-
forms the antidoping environment. The deterrent effect of
delayed testing with newly devised analytical methods is sub-
stantial. It is important that ADOs implement this process; the
new 2015 International Standard on Testing and Investigations
sets out the requirements for ADOs to test, store and reanalyse
samples. The IFs and other ADOs must prioritise which samples
should be stored from which competitions on the basis of their
risk assessments. Such decisions should, to the extent permis-
sible under applicable laws, remain conﬁdential to optimise the
deterrent and detection elements of this new approach to
doping control. It is important that the storage of samples be
conducted in a manner that enables future analysis with
methods that may not yet be fully developed or operational. An
example would be the future analysis of molecular signatures of
doping (see article by Pitsiladis et al).6 It is also imperative that
samples are stored in a manner that protects the integrity of bio-
logical samples and the antidoping process, having due regard
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to legal requirements surrounding handling of human biological
materials and related data.5
Analytical challenges
The continuously growing knowledge in medicine, molecular
biology, biochemistry and biotechnology has substantially
expanded the options to pharmacologically manipulate the
performances of athletes. Unsurprisingly, this has resulted in the
suspected and proven misuse of a wide range of peptide hor-
mones and substances such as insulin, insulin-like growth factor
1, human growth hormone (hGH), epoetins, chorionic gonado-
trophins, gene doping substances including RNA interference
(RNAi), ‘designer drugs’ (eg, Tetrahydrogestrinone) as well as
non-approved, emerging or discontinued compounds (eg,
aminoimidazolecarboxamideriboside-AICAR, GW1516, selective
androgen receptor modulators, hypoxia-inducible factor stabili-
sers and erythropoietin (Epo)-mimetic agents). These develop-
ments represent a considerable analytical challenge for
antidoping scientists, which require dedicated research and the
development of new methodologies. Concerted activities with
civil authorities are also necessary to understand and combat the
changing scope of doping practices and products.7
Analytically, the issue of new, discontinued, or ‘tailored’ drug
entities has been successfully tackled by applying non-target/
open approaches, biomarker-based assays (eg, haematological,
steroidal and endocrinological modules of the ABP), ‘omics’
strategies and monitoring effects of drug (mis)use rather than
the administered drug. This has been carried out via proactive
and retrospective monitoring programmes. Some recent suc-
cesses include the introduction of section ‘S.0’ to the WADA
Prohibited List, new detection methods for the determination of
RNAi-based compounds in blood and urine, the analysis of Epo
microdosing, adverse analytical ﬁndings for the non-approved
drugs GW1516, andarine and ostarine, as well as new methods
to detect the illicit use of natural compounds such as AICAR.7–9
Forensic intelligence
The importance of investigations is enhanced in the 2015 World
Anti-Doping Code10 to further encourage ADOs to pursue anti-
doping violations based on the strongest evidence possible.
While investigations as the primary means of proving doping
violations are uncommon in sport, investigations have been suc-
cessful in highlighting doping practices and developing novel
approaches in the ﬁght against doping in sport.
High-proﬁle investigations include the Bay Area Laboratory
Co-Operative (BALCO) investigation that was undertaken in the
USA in 2003.This case resulted in the prosecution of several
athletes for the use of hGH and new designer steroids and led
to new laboratory detection capabilities and changes to the
World Anti-Doping Code.11 12 In 2006, a Spanish investigation
code-named Operation Puerto highlighted serious doping prac-
tices involving Dr Eufemiano Fuentes and a number of elite
athletes.13 14
In 2013, the Australian Crime Commission uncovered links
between organised crime and professional sporting teams and
the use of performance-enhancing ‘peptides’ and other illicit
substances.15 This investigation led to a team in the Australian
Football League being charged and subsequently sanctioned.16
At the heart of this case were the activities of support staff.
Therefore, it follows that close scrutiny of support staff is expli-
cit in the 2015 World Anti-Doping Code. The successful conclu-
sion of each of these highlighted cases relied on forensic science
and other modern investigative techniques now at the disposal
of IFs and NADOs and in accordance with the investigation
aspects of the 2015 World Anti-Doping Code.
A forensic intelligence model of antidoping investigations was
proposed by Marclay et al17 and included broader exploitation
of information held at different levels by antidoping partners
such as the police, borders agencies and postal services, strategic
Internet monitoring, physical and chemical drug proﬁling and
doping script analysis within a forensic intelligence framework.
Tactical use of forensic intelligence tools relies largely on the
exploitation of bioanalytical results, documents linked to doping
practice and seizures of prohibited substances. At the oper-
ational level, the exploitation of such information serves to
uncover trends related to the abuse of prohibited substances, the
existence of organised doping programmes including the traf-
ﬁcking of doping agents, and helps identify their structure and
mechanisms of operation. Strategic Internet monitoring also
allows the identiﬁcation and monitoring of online sales websites,
forums, blogs, social networks and other online media, thus
helping to create a clearer picture of the market and emergence
of new trends.18 Monitoring of the physical and chemical pro-
ﬁles of seized products further enhances the understanding of
the organisational structure of the trafﬁcking of prohibited sub-
stances.19 Drug proﬁling as well as digital and other data allow
the building of ‘inference models’ that can link to product sei-
zures, highlight distribution networks and identify the sources
of supply. Finally, script analysis can map the complete sequence
of activities before, during and after doping to identify the key
stages and possible intervention points where the doping
process might be disrupted or even prevented.20
Psychological approach to optimise most deterrent effect
The perception of the likelihood of detection, the severity of
the penalty and the speed with which sanctions will be applied
all appear to deter doping behaviour.21 Better understanding of
doping deterrents will enhance doping control programmes and
reinforce the need for testing strategies to be carefully consid-
ered, strategically applied and robustly enforced.
The sense of ‘right and wrong’ and the perception of normative
behaviour within a sport community are perhaps the most funda-
mental determinants of appropriate sporting behaviour.22–24
Doping practices have been mostly embedded in sports in which it
was widely understood that such behaviours were part of the sport
‘culture’. Therefore, sport organisations should consistently
emphasise that drug-taking behaviour is fundamentally contrary to
the principles and precepts of sport, that is, against the spirit
of sport.
Sport can profoundly mould and modify attitudes and beliefs.
The clear, unequivocal expression of a set of expectations
regarding conduct and behaviour within a sport can have a
powerful and enduring impact. The degree to which these
expectations are upheld by athletes can enhance their legitimacy
in the eyes of their fellow competitors and strengthen the per-
ception that violations of such expectations are wrong. The pro-
found disapproval that follows the violation of broadly valued
standards of behaviour can be an immensely powerful sanction
and the desire to avoid such disapproval an equally potent
deterrent. Therefore, the creation of what has been described as
a ‘moral cosmology’ and an associated ‘moral community’ is
central to the development of a sporting community in which
doping practices are reduced to an absolute minimal level
(accepting that there will always be those who succumb in sport,
as elsewhere, to the temptation to cheat).21 25
Dvorak J, et al. Br J Sports Med 2014;48:801–806. doi:10.1136/bjsports-2014-093561 3 of 6
Consensus statement
The ABP and confounding factors
Typical doping control based on the direct detection of a sub-
stance or its metabolites is an effective approach. However, it
has limitations particularly when an athlete may be using sub-
stances on an intermittent and/or low-dose basis, which may
therefore go undetected under even the most robust
In-of-Competition and Out-of-Competition Doping Control
programme. Furthermore, the availability of substances virtually
identical to those produced by the human body, such as the
native form of Epo, testosterone and growth hormone necessi-
tated a new drug-testing paradigm.
Longitudinal proﬁling, which eventually became harmonised
into the scientiﬁcally robust WADA ABP programme, is a com-
plementary and alternative means to traditional doping control.
Doping leaves a characteristic ‘ﬁngerprint’ on the biology of the
athlete and the ABP is used to identify that ﬁngerprint, and thus
the occurrence of doping. Once a biomarker of doping is imple-
mented in the ABP, the potential to detect those changes
brought on by performance-enhancing drugs is increased; it
may prove possible to detect changes caused by substances that
have not yet been identiﬁed.26
The intelligent and timely interpretation of ABP data can lead
to target testing for speciﬁc substances. Alternatively, an atypical
passport ﬁnding which is conﬁrmed by an Expert Panel can lead
to an athlete being charged with an antidoping rule violation
without a ‘positive’ test (Adverse Analytical Finding). Thus, the
ABP can be seen as an innovative and reliable antidoping tool as
reﬂected by the ﬁndings of Court of Arbitration for Sport
panels in several cases. The introduction of the ABP also pro-
vides a strong doping deterrent and a boost to the credibility of
the ﬁght against doping in any given sport.27 The ABP does not
only involve the monitoring of biological markers. Confounding
factors such as age, sex and exposure to higher altitude for the
haematological module are also included in the passport for
improved decision-making.28 Several confounding factors are
also described in the WADA 2014 endogenous anabolic steroids
technical document (TDEAAS2014).29 Detailed information
regarding sample collection, transport and analysis is included
in the technical documents that accompany the WADA ABP
Operating Guidelines.28
Data management system—Anti-Doping Administration &
Management System
Regardless of advancements in science and enhanced antidoping
practice and policy, the ﬁght against doping in sport can only
succeed if there is a coordinated effort to ensure that the limited
resources are used effectively. In this regard, the collection, ana-
lysis and sharing of doping control-related information and
intelligence are imperative. Only by using a single database
to collect and disseminate such information can the global anti-
doping community intelligently coordinate their efforts.
Anti-Doping Administration & Management System (ADAMS)
provided by WADA, adapts to support the ever-changing anti-
doping environment. A single database also ensures consistency
in protecting the rights of athletes vis-à-vis their information
and ever-emerging data protection best practices.
Education
One of the objectives of successful antidoping education is to
ensure that all those involved in sport understand the harm
caused by doping to the health of athletes and to the integrity
and essence of sport. As all sport-related stakeholders have a
role to play to promote clean sport, educational efforts must be
inclusive of the broad sporting community including athletes,
coaches, physicians, teachers and parents. This objective will
require the commitment of the IOC, IFs, governments (to reach
schools and community-level sport) and NADOs, with WADA
as the coordinator.
Education should be ongoing and sustained; it must take
place throughout the entire sporting career of an individual and
focus on values and good decision-making skills as well as an
appreciation of the roles and responsibilities of athletes. The
education of athletes has to start as early as possible, preferably
prior to an athlete’s ﬁrst national/international competition. For
example, FIFA introduced a standard educational programme to
all participating teams of the FIFA U-17 World Cup (boys and
girls) 2012 that was overseen by doctors responsible for the
competition. This is in addition to other grassroot education
programmes already implemented by organisations such as
UEFA that involve the education of more than 1000 young
international football players each year. For the success of these
programmes, the message presented to athletes needs to be clear
and at the correct level. The use of posters, to decorate the typ-
ically ‘unfriendly’ surroundings, and advice cards could also
facilitate such communication.
Research needs and necessary advances
Approaches to detect doping have improved signiﬁcantly in
recent years but remain imperfect and therefore new direct and
indirect detection methods are required. New integrative
‘Omics’-based solutions are being developed that have the
potential to improve the analytical performance of current
detection methods.30 In particular, WADA is funding studies to
identify a ‘molecular signature’ of recombinant human erythro-
poietin (RhumanEpo) doping and preliminary results are prom-
ising.31 For example, in the ﬁrst systematic study to be
conducted, the expression of hundreds of genes were found to
be altered by RhumanEpo with numerous gene transcripts being
differentially expressed after the ﬁrst injection and further tran-
scripts profoundly upregulated during and subsequently down-
regulated up to 4 weeks postadministration of the drug, with
the same transcriptomic pattern observed in all participants.
The identiﬁcation of a blood ‘molecular signature’ of
RhumanEpo administration is the strongest evidence to date
that gene biomarkers have the potential to substantially improve
the analytical performance of current antidoping methods such
as the ABP for RhumanEpo detection. These encouraging
results serve to strongly reinforce the feasibility and need for
this complex, expensive and technically demanding approach
involving leading industry partners for the detection of banned
substances and methods. Therefore, research using an ‘omics’-
based approach involving genomics, transcriptomics, proteomics
and metabolomics should be greatly intensiﬁed in order to
achieve improved detection of Recombinant human Epo and
other doping substances and methods difﬁcult to detect such as
growth hormone and blood transfusions.
Inadvertent doping
A major objective of the global ﬁght against doping is the pro-
tection of the clean athlete, and hence the need to inform ath-
letes of the risks of inadvertent doping. In recent years,
antidoping research has identiﬁed contaminated nutritional sup-
plements and food as the principal sources of inadvertent
doping. Nutritional supplements have been contaminated with
various stimulants, β2-agonists, prohormones, ‘classic’ anabolic
steroids and non-approved designer steroids.32 33
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Similarly, the consumption of certain foods, especially meat
products, is of particular concern as they may result in an
adverse analytical ﬁnding. Recent investigations have shown that
the anabolic agent clenbuterol is misused in some countries as a
growth promoter in cattle feeding. The consumption of meat
from clenbuterol-treated cattle may lead to adverse analytical
ﬁndings and to poisoning cases.34 35 WADA has communicated
with speciﬁc governments to address this concern as it relates to
doping and sport. WADA and FIFA are also working on studies
that may differentiate the source of clenbuterol to detect
whether the substance found in the body may be due to an
indirect ingestion from an animal product. First promising
results have already been obtained.36 37 The identiﬁcation of
such ‘doping traps’ and the dissemination of the knowledge of
such sources of inadvertent doping to all stakeholders are
important aspects in the protection of athletes.
Management and ethics: biological data
The introduction of the ABP is a reason to consider expanding
the role of the medical profession in the ﬁght against doping in
sport. The ABP is a recently validated approach to the identiﬁca-
tion and prosecution of doping rule violations. The routine
implementation of the ABP may result in the inadvertent identi-
ﬁcation of potential clinical situations and this will need to be
addressed by medical experts. When alerted to laboratory ﬁnd-
ings, physicians are obliged to inform the athlete via the ADOs
if there is a suspected pathology. ADOs, particularly the IFs and
the NADOs, must respond accordingly to ensure the appropri-
ate involvement of medical professionals in the process of indi-
vidual case management. At present, the mandate of ADOs is
primarily to ensure that the health of the athlete is not affected
by entering a doping spiral rather than as a health check system,
and the process typically does not involve a physician. New
rules would be required to address this issue.5
Whenever doctors afﬁliated with ADOs are involved in
results management, they must ensure that anomalous results of
potential clinical signiﬁcance are investigated appropriately. In
such situations, communication with other physicians involved
in the care of the particular athlete outlining the ﬁndings, their
implication and suggesting, when necessary, an approach to
their further investigation has been a common approach. It is
unreasonable to expect that non-physicians would have the
training, experience or perspective to assume responsibility for
such a process. The management of such cases requires distinct
medical knowledge and clinical experience.
The introduction of the ABP has raised a number of questions
that reﬂect a profound concern for issues of conﬁdentiality and
the responsibility of those in receipt of biological information to
take action if and when information that may relate to the
health of a competitor becomes apparent. There may be
signiﬁcant national considerations to take into account in such
circumstances. In some jurisdictions, testing authorities and
laboratories are not considered or accredited as providing
healthcare-related services and the disclosure of information
emanating from such facilities, subsequently used for clinical
purposes, may jeopardise such accreditation. Clearly, there is no
expectation that analytical laboratories should see their role as
expanding into ‘clinicopathological’ domains. The identiﬁcation
of anomalous ﬁndings by a clinician should be seen as an en
passant phenomenon occasioned by a clinician’s review of anti-
doping laboratory results and prompting further clinical-
standard investigations. The activities of clinicians in this respect
should not be misinterpreted as evidence that antidoping
analyses reﬂect clinical activities on the part of the antidoping
laboratory.
However, clinicians would argue that they have a fundamental
ethical responsibility to take action when provided with infor-
mation that may reﬂect an underlying pathological condition.
Physicians are obliged to alert the ADOs if they note anomalous
results that are suspicious of pathology. The assessment of
results by laboratory and medical experts (as part of the ABP) is
carried out anonymously, therefore contact must be made via
the ADO. Notably, in urine samples from male athletes, an ele-
vation of the levels of human choriogonadotropin hormone
(hCG) is quite common with approximately 90 cases a year
according to WADA statistics.38 Elevated hCG may be due to
the intake of the exogenous hormone but could reﬂect an
underlying pathology—most typically testicular cancer. For all
such cases, a specialised medical examination must be recom-
mended as soon as possible to ensure appropriate investigation
and treatment. Physicians experienced in providing oversight to
antidoping programmes are familiar with this scenario and
understand the importance of their intervention to ensure that
proper clinical attention is given to the athletes concerned.
WADA has provided clear instructions to ADOs to contact ath-
letes to seek further medical investigation when elevated hCG
levels are detected. There are a number of documented cases
where such early intervention has led to a complete cure of the
underlying condition and can be seen as an extremely positive
aspect of doping control activities. hCG testing is part of
routine analytical doping tests and not part of the ABP.
Equally challenging is the question of the right of competitors
to have access to their test results. This is a complex and highly
problematic issue given that such access may allow doping com-
petitors to manipulate or modify their strategies so as to be
more likely to escape detection. Furthermore, national legisla-
tion may, in many jurisdictions, mandate the release of such
information; the question of the timing of such release may be
critically important in ensuring the integrity of the testing
system. These challenges notwithstanding, the importance to
protect the data accumulated in the conduct of doping control
programmes is paramount. It is important for sport organisa-
tions and their ofﬁcials and staff to understand the robust and
rigorous approaches that are used to safeguard personal health
and related biological information in other community settings.
Summary and conclusions
The purpose of this paper was to summarise the results of the
consensus meeting on Anti-Doping in Sport sponsored by FIFA.
The participants achieved consensus on a strategy for the imple-
mentation of the 2015 World Anti-Doping Code. Key compo-
nents of this strategy include: (1) sport-speciﬁc risk assessment,
(2) prevalence measurement, (3) sport-speciﬁc test distribution
plans, (4) storage and reanalysis, (5) analytical challenges,
(6) forensic intelligence, (7) psychological approach to optimise
most deterrent effect, (8) ABP and confounding factors, (9) data
management system (ADAMS), (10) education, (11) research
needs and necessary advances, (12) inadvertent doping and
(13) management and ethics: biological data. True implementa-
tion of the 2015 World Anti-Doping Code will depend largely
on the ability to align thinking around these core concepts and
strategies. FIFA, jointly with all other engaged IFs, the IOC and
WADA are ideally placed to lead transformational change with
the unwavering support of the wider antidoping community.
The outcome of the consensus meeting was the creation of the
ad hoc Working Group charged with the responsibility of
moving this agenda forward.
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